Overview

Study of CS-3150 in Patients With Essential Hypertension

Status:
Completed
Trial end date:
2017-07-11
Target enrollment:
Participant gender:
Summary
To evaluate antihypertensive effect and safety of CS-3150 compared to Eplerenone in patients with essential hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Treatments:
Eplerenone
Mineralocorticoid Receptor Antagonists
Spironolactone